585.49
24.00 (4.27%)
| Previous Close | 561.49 |
| Open | 565.50 |
| Volume | 979,152 |
| Avg. Volume (3M) | 998,927 |
| Market Cap | 64,198,975,488 |
| Price / Earnings (TTM) | 15.27 |
| Price / Earnings (Forward) | 13.32 |
| Price / Sales | 4.55 |
| Price / Book | 2.09 |
| 52 Weeks Range | |
| Earnings Date | 29 Apr 2025 |
| TTM Dividend Yield | 0.15% |
| Profit Margin | 31.07% |
| Operating Margin (TTM) | 26.91% |
| Diluted EPS (TTM) | 38.35 |
| Quarterly Revenue Growth (YOY) | 10.30% |
| Quarterly Earnings Growth (YOY) | -20.90% |
| Total Debt/Equity (MRQ) | 10.01% |
| Current Ratio (MRQ) | 4.73 |
| Operating Cash Flow (TTM) | 4.42 B |
| Levered Free Cash Flow (TTM) | 2.64 B |
| Return on Assets (TTM) | 7.31% |
| Return on Equity (TTM) | 15.95% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Regeneron Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 3.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -2.5 |
| Average | 1.00 |
|
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Value |
| % Held by Insiders | 1.58% |
| % Held by Institutions | 91.88% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 1,013.00 (Piper Sandler, 73.02%) | Buy |
| Median | 842.00 (43.81%) | |
| Low | 547.00 (B of A Securities, -6.57%) | Sell |
| Average | 823.30 (40.62%) | |
| Total | 7 Buy, 2 Hold, 1 Sell | |
| Avg. Price @ Call | 619.82 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 25 Apr 2025 | 652.00 (11.36%) | Hold | 585.49 |
| 05 Feb 2025 | 759.00 (29.64%) | Hold | 716.72 | |
| Truist Securities | 23 Apr 2025 | 975.00 (66.53%) | Buy | 585.49 |
| Canaccord Genuity | 22 Apr 2025 | 850.00 (45.18%) | Buy | 585.49 |
| Cantor Fitzgerald | 22 Apr 2025 | 695.00 (18.70%) | Buy | 585.49 |
| B of A Securities | 17 Apr 2025 | 547.00 (-6.57%) | Sell | 563.16 |
| Goldman Sachs | 14 Apr 2025 | 917.00 (56.62%) | Buy | 571.06 |
| JP Morgan | 31 Mar 2025 | 1,000.00 (70.80%) | Buy | 634.23 |
| Leerink Partners | 05 Feb 2025 | 834.00 (42.44%) | Buy | 716.72 |
| Citigroup | 28 Jan 2025 | 750.00 (28.10%) | Hold | 686.33 |
| Piper Sandler | 27 Jan 2025 | 1,013.00 (73.02%) | Buy | 684.71 |
| Show more | ||||
No data within this time range.
| TTM Dividend Yield | 0.15% |
| Expected Next Dividend Payment | Mar 2026 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 20 Feb 2025 | - | 20 Mar 2025 | 0.88 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2025 | 0.880 | 1 | 0.15 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |